To hear about similar clinical trials, please enter your email below
Trial Title:
Vitreous Level Of Tumor Necrosis Factor Alpha In Patients With Retinal Vein Occlusion
NCT ID:
NCT05532475
Condition:
Retinal Vein Occlusion
Conditions: Official terms:
Retinal Vein Occlusion
Necrosis
Conditions: Keywords:
Tumor necrosis factor alpha
Study type:
Observational
Overall status:
Unknown status
Study design:
Time perspective:
Cross-Sectional
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
measurement of vitreous level of tumor necrosis factor alpha
Description:
measurement of vitreous level of tumor necrosis factor alpha using ELISA technique
Arm group label:
cases
Arm group label:
control
Summary:
To assess the levels of TNF- α in vitreous samples of patients with retinal vein
occlusion prior to administration of intravitreal anti-VEGF and compare them to levels in
vitreous samples of normal subjects so as to investigate the association of vitreous
tumor necrosis factor with the pathogenesis of retinal vein occlusion.
Criteria for eligibility:
Study pop:
Retinal venous occlusion patients admitted in KasrAlainy Hospital for Intravitreal
Injection of Lucentis (Cases) compared to patient without retinal vein occlusion admitted
for cataract surgery (Controls).
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- Any patient with retinal vein occlusion not older than 6 months with no history of
Anti-VEGF injection
Exclusion Criteria:
1. Diabetic patients.
2. Other causes of retinal vascular diseases.
3. Patients with history of treatment of retinal vein occlusion.
4. Previous intraocular surgery except cataract surgery performed 6 months before the
study.
5. Subjects with severe systemic inflammatory diseases
6. Retinal vein occlusion secondary to retinal vasculitis.
7. All retinal pathologies.
8. Patients receiving Systemic steroids or Immunosuppressive therapy.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Kasr ALainy University hospital
Address:
City:
Cairo
Zip:
12916
Country:
Egypt
Status:
Recruiting
Contact:
Last name:
Mohamed A Attya, M.D.
Phone:
00201113332892
Email:
mohamed.attya86@cu.edu.eg
Start date:
March 12, 2022
Completion date:
October 2022
Lead sponsor:
Agency:
Kasr El Aini Hospital
Agency class:
Other
Source:
Kasr El Aini Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05532475
